SARS-CoV-2 spike E484K mutation reduces antibody neutralisation

Ítems similars

• The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
  per: Jangra, Sonia, et al.
  Publicat: (2021)
• Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse model
  per: Amanat, Fatima, et al.
  Publicat: (2020)
• Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model
  per: Amanat, Fatima, et al.
  Publicat: (2021)
• Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection
  per: Rathnasinghe, Raveen, et al.
  Publicat: (2020)
• Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection
  per: Rathnasinghe, Raveen, et al.
  Publicat: (2020)